Previously, we have demonstrated the role of MAPK/ERK1/2 and PI3K/AKT signaling at the onset and maintenance of platinum-taxol resistance in ovarian cancer cells [15], [16], [17]. This evidence concerns the gene MAPK3 and ovarian carcinoma.